This Study in Healthy Men Tests How Different Doses of BI 1265162 Are Taken up in the Body and How Well They Are Tolerated.
- First Posted Date
- 2018-07-03
- Last Posted Date
- 2022-02-23
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 50
- Registration Number
- NCT03576144
- Locations
- 🇩🇪
CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany
This Study is Done in Healthy Japanese Volunteers. It Looks at How Different Doses of BI 1015550 Are Taken up in the Body and How Well They Are Tolerated.
- First Posted Date
- 2018-05-31
- Last Posted Date
- 2022-12-14
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 16
- Registration Number
- NCT03542344
- Locations
- 🇯🇵
SOUSEIKAI Sumida Hospital, Tokyo, Sumida-ku, Japan
The SUSTAIN Study Compares the Effects of Sustained and Immediate-release Pramipexole on the noctUrnal Symptoms of paTients With Advanced ParkInsoN's Disease Who Also Take L-Dopa
- First Posted Date
- 2018-05-11
- Last Posted Date
- 2021-02-16
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 98
- Registration Number
- NCT03521635
- Locations
- 🇨🇳
The First Afiliated Hospital, Sun Yet-sen University, Guangzhou, China
🇨🇳Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
🇨🇳Wuhan Union Hospital, Wuhan, China
This Study in Healthy Men and Women Tests How the Body Takes up BI 409306
- First Posted Date
- 2018-04-23
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 9
- Registration Number
- NCT03505151
- Locations
- 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany
Digital Auscultation Test - IPF Data Collection
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Device: Littmann ®
- First Posted Date
- 2018-04-19
- Last Posted Date
- 2020-01-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 274
- Registration Number
- NCT03503188
- Locations
- 🇩🇪
Klinikum Chemnitz gGmbH, Chemnitz, Germany
🇩🇪Ruhrlandklinik, Westdeutsches Lungenzentrum am Universitätsklinikum Essen gGmbH, Essen, Germany
🇩🇪Fachkrankenhaus Coswig GmbH, Coswig, Germany
This Study in Healthy Men Tests How the Body Takes up BI 1467335
- Conditions
- Healthy
- Interventions
- Drug: BI 1467335 (C-14) intravenous solution
- First Posted Date
- 2018-03-30
- Last Posted Date
- 2021-07-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 12
- Registration Number
- NCT03483506
- Locations
- 🇳🇱
PRA Health Sciences Onderzoekscentrum Martini, Groningen, Netherlands
This Study in Healthy Volunteers Determines the Amount of BI 730460 in the Blood When Taken as Tablet. It Looks at How Different Doses of BI 730460 Are Taken up in the Body and How Well They Are Tolerated. The Study Also Tests How Food Influences the Amount of BI 730460 in the Blood.
- First Posted Date
- 2018-03-29
- Last Posted Date
- 2022-08-10
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 48
- Registration Number
- NCT03483077
- Locations
- 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany
BI655130 (SPESOLIMAB) Induction Treatment in Patients With Moderate-to-severe Ulcerative Colitis
- First Posted Date
- 2018-03-29
- Last Posted Date
- 2021-06-11
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 98
- Registration Number
- NCT03482635
- Locations
- 🇨🇦
University of Manitoba - Health Sciences Centre, Winnipeg, Manitoba, Canada
🇷🇺FSB Instit. HC Irkutsk Scient.Cent. Sibirian Branch of Russ. Acad. Scien., Irkutsk, Russian Federation
🇩🇪Medizinische Hochschule Hannover, Hannover, Germany
A Study to Test Different Doses of BI 836880 Combined With Ezabenlimab in Patients With Advanced Non-small Cell Lung Cancer Followed by Other Types of Advanced Solid Tumours
- Conditions
- NeoplasmsNon-squamous, Non-Small-Cell Lung Cancer
- Interventions
- First Posted Date
- 2018-03-16
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 252
- Registration Number
- NCT03468426
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Beverly Hills Cancer Center, Beverly Hills, California, United States
🇺🇸Winship Cancer Institute, Atlanta, Georgia, United States
Empa PASS on Urinary Tract Malignancies
- First Posted Date
- 2018-03-13
- Last Posted Date
- 2025-04-20
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 344995
- Registration Number
- NCT03464045
- Locations
- 🇬🇧
United Kingdom Clinical Practice Research Datalink (CPRD), London, United Kingdom
🇸🇪The Swedish prescribed drug register, Stockholm, Sweden
🇫🇮The National Register Data, Helsinki, Finland